Answer
Atezolizumab directly binds PD-L1, blocking its interactions with PD-1 and B7.1 to release PD-L1/PD-1-mediated immune inhibition and reactivate the antitumour immune response without inducing antibody-dependent cellular cytotoxicity, while preserving PD-L2/PD-1 inhibitory signalling.
Sources for this answer
- Tecentriq 840 mg and 1,200 mg concentrate for solution for infusionRoche Products Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 44Document updated
Sources checked